In Treatment of Malaria Malaria is a serious or life-threatening illness that is spread by a parasite that enters the human body by the bite of infected mosquitoes. Falcigo Plus Tablet is an antimalarial medicine and is used to treat malaria. It kills the infection-causing parasite and stops the further spread of the infection in the body. Do not use this medicine for treating any other condition without consulting your doctor.
Caution is advised when consuming alcohol with Falcigo Plus Tablet. Please consult your doctor.
Falcigo Plus Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Falcigo Plus Tablet is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Falcigo Plus Tablet may cause side effects which could affect your ability to drive. Falcigo Plus Tablet can cause dizziness, loss of balance and mental problems and this may affect your ability to drive.
There is limited information available on the use of Falcigo Plus Tablet in patients with kidney disease. Please consult your doctor.
Falcigo Plus Tablet should be used with caution in patients with liver disease. Dose adjustment of Falcigo Plus Tablet may be needed. Please consult your doctor. Use of Falcigo Plus Tablet is not recommended in patients with severe liver disease.
If you miss a dose of Falcigo Plus Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More